Jorgensen is set to testify before a Senate committee on Tuesday in a hearing focused on U.S. prices for its widely popular ...

Lawmakers are set to scrutinize the high cost of weight loss and diabetes drugs, which depending upon your insurance can ...

The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo ...

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

It's the second lawsuit to be filed this year in Maine against insurance carriers that limit coverage of popular drugs like ...

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

As a possible indication that the hearing, which starts at 10a ET, could get contentious, it has the title, "Why is Novo ...

Novo Nordisk CEO Lars Jergensen testified on the company's pricing for its diabetes and weight loss drugs, Ozempic and Wegovy, respectively. Public affairs events, congressional hearings, speeches, ...

According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...

Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...